We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NVAX beat Q2 earnings and revenue estimates despite a sharp year-over-year decline in total revenues.
Novavax raised its 2026 adjusted revenue outlook and lowered combined R&D and SG&A expense guidance.
NVAX highlighted potential Sanofi milestone payments and progress in Matrix-M and C. Diff vaccine programs.
Novavax (NVAX - Free Report) incurred a loss of 32 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 36 cents. In the year-ago quarter, the company had recorded earnings per share (EPS) of 62 cents, driven by milestone-related payments.
Quarterly revenues totaled $56.7 million, down 76% year over year. Yet, this metric beat the Zacks Consensus Estimate of $50 million.
Shares of Novavax have increased 14% so far this year compared with the industry’s 4% growth.
Image Source: Zacks Investment Research
NVAX's Revenue Mix Shifts Toward Partners
As the company’s partner, Sanofi (SNY - Free Report) , has assumed commercial responsibility for marketing its COVID-19 vaccine Nuvaxovid, it did not record any direct product sales. Novavax recorded supply sales worth $19 million, up 47% year over year, supported by higher demand for the Matrix-M adjuvant from partners as well as COVID-19 supply to its license partners.
Licensing, royalties and other revenues fell 83% to $37.8 million, almost entirely generated from Sanofi. The prior-year quarter benefited from a $175 million milestone payment from SNY and $27 million received from Takeda.
Novavax Cuts Costs as Operating Model Gets Leaner
Research and development (R&D) expenses declined 11% year over year to $70.7 million. This figure does not include the $22.6 million of R&D reimbursement from Sanofi.
Selling, general and administrative (SG&A) expenses fell 39% to $26.7 million, primarily due to the transition of lead commercial activities to Sanofi and the elimination of Novavax’s commercial infrastructure.
As of June 30, 2026, Novavax had $724 million in cash and cash equivalents compared with $795 million in the previous quarter.
NVAX Improves 2026 Outlook
With Sanofi leading commercialization in key COVID-19 markets, NVAX continues to emphasize an adjusted revenue framework rather than total revenue guidance. For 2026, the company raised its adjusted total revenue outlook to $235-$275 million from $230-$270 million. The framework excludes Sanofi supply sales, royalties and milestones.
NVAX lowered its 2026 combined R&D and SG&A expense guidance to $370-$410 million from $380-$420 million. Expected R&D reimbursements from Sanofi were revised to $60-$70 million from $70-$80 million.
The company reiterated that adjusted combined R&D and SG&A expenses, net of partner reimbursements, are expected in the $150-$200 million range in 2028.
NVAX Sees Sanofi Milestones Ahead
Sanofi is in advanced discussions with regulators regarding the timing of a phase III study on its COVID-19-influenza combination vaccine. Initiation of the study in the United States or the European Union would trigger a $125 million milestone payment to Novavax.
The Nuvaxovid manufacturing technology transfer to Sanofi is expected to be completed in mid-2027, triggering another $75 million milestone. Management expects that payment to extend the company's cash runway from 2028 into 2029.
Novavax Advances Matrix-M and C. Diff Programs
The company emphasized that four of the top 10 pharmaceutical companies now have licensing agreements or material transfer agreements involving Matrix-M. This includes a non-exclusive agreement signed with Pfizer (PFE - Free Report) earlier this year. Multiple partner-led experiments are underway across infectious disease and oncology, including a recent oncology MTA with a leading global pharmaceutical company.
The company also advanced its multivalent Clostridium difficile colitis (C. Diff.) vaccine candidate into pre-IND interactions with the FDA and initiated GMP manufacturing. The program remains on track for potential clinical entry as early as 2027, while the next tranche of Matrix-M data from evaluations with commercial vaccines is expected by early 2027.
View the Zacks #1 Rank List
Image: Shutterstock
NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised
Key Takeaways
Novavax (NVAX - Free Report) incurred a loss of 32 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 36 cents. In the year-ago quarter, the company had recorded earnings per share (EPS) of 62 cents, driven by milestone-related payments.
Quarterly revenues totaled $56.7 million, down 76% year over year. Yet, this metric beat the Zacks Consensus Estimate of $50 million.
Shares of Novavax have increased 14% so far this year compared with the industry’s 4% growth.
Image Source: Zacks Investment Research
NVAX's Revenue Mix Shifts Toward Partners
As the company’s partner, Sanofi (SNY - Free Report) , has assumed commercial responsibility for marketing its COVID-19 vaccine Nuvaxovid, it did not record any direct product sales. Novavax recorded supply sales worth $19 million, up 47% year over year, supported by higher demand for the Matrix-M adjuvant from partners as well as COVID-19 supply to its license partners.
Licensing, royalties and other revenues fell 83% to $37.8 million, almost entirely generated from Sanofi. The prior-year quarter benefited from a $175 million milestone payment from SNY and $27 million received from Takeda.
Novavax Cuts Costs as Operating Model Gets Leaner
Research and development (R&D) expenses declined 11% year over year to $70.7 million. This figure does not include the $22.6 million of R&D reimbursement from Sanofi.
Selling, general and administrative (SG&A) expenses fell 39% to $26.7 million, primarily due to the transition of lead commercial activities to Sanofi and the elimination of Novavax’s commercial infrastructure.
As of June 30, 2026, Novavax had $724 million in cash and cash equivalents compared with $795 million in the previous quarter.
NVAX Improves 2026 Outlook
With Sanofi leading commercialization in key COVID-19 markets, NVAX continues to emphasize an adjusted revenue framework rather than total revenue guidance. For 2026, the company raised its adjusted total revenue outlook to $235-$275 million from $230-$270 million. The framework excludes Sanofi supply sales, royalties and milestones.
NVAX lowered its 2026 combined R&D and SG&A expense guidance to $370-$410 million from $380-$420 million. Expected R&D reimbursements from Sanofi were revised to $60-$70 million from $70-$80 million.
The company reiterated that adjusted combined R&D and SG&A expenses, net of partner reimbursements, are expected in the $150-$200 million range in 2028.
NVAX Sees Sanofi Milestones Ahead
Sanofi is in advanced discussions with regulators regarding the timing of a phase III study on its COVID-19-influenza combination vaccine. Initiation of the study in the United States or the European Union would trigger a $125 million milestone payment to Novavax.
The Nuvaxovid manufacturing technology transfer to Sanofi is expected to be completed in mid-2027, triggering another $75 million milestone. Management expects that payment to extend the company's cash runway from 2028 into 2029.
Novavax Advances Matrix-M and C. Diff Programs
The company emphasized that four of the top 10 pharmaceutical companies now have licensing agreements or material transfer agreements involving Matrix-M. This includes a non-exclusive agreement signed with Pfizer (PFE - Free Report) earlier this year. Multiple partner-led experiments are underway across infectious disease and oncology, including a recent oncology MTA with a leading global pharmaceutical company.
The company also advanced its multivalent Clostridium difficile colitis (C. Diff.) vaccine candidate into pre-IND interactions with the FDA and initiated GMP manufacturing. The program remains on track for potential clinical entry as early as 2027, while the next tranche of Matrix-M data from evaluations with commercial vaccines is expected by early 2027.
Novavax, Inc. Price
Novavax, Inc. price | Novavax, Inc. Quote
NVAX’s Zacks Rank
Novavax currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.